Market atlas / Incretins / Dulaglutide

Dulaglutide (GLP-1 agonist)

repurposedbiologicglp1-receptor-agonismmetabolicweight-loss● body-weight● hba1c

Stage by geography

Same development stage across markets, but United Kingdom reached it about 11 years before China.

signalpreclinfirst-in-humanRCTapprovedreal-worldconsumerUSUKCNJPCHSGILKRIN+1 stages

MarketsUS United States FDAUK United Kingdom MHRA / NICECN China NMPAIN India CDSCOJP Japan PMDACH Switzerland SwissmedicSG Singapore HSAIL Israel Ministry of HealthKR South Korea MFDS

What each market approved it for

Market	Stage	Since	Indication / class / form
US	approved	not dated	class GLP-1 Receptor Agonist [EPC]
UK	approved	2014-11-21	indication Type 2 Diabetes Mellitus Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an…
CN	approved	2025-08-05	form Injection, biologic
IN	RCT	2026-09-01	not published
JP	approved	2015-07-03	indication A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus.
CH	approved	2015-05-06	indication Antidiabetic, prevention of cardiovascular events
SG	approved	2016-03-18	form Injection, solution, subcutaneous, prescription only
IL	approved	2020-08-31	indication Type 2 Diabetes Mellitus Trulicity is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and…
KR	approved	2015-05-26	class Diabetes agents [MFDS 03960]

China registers · NMPA

What each NMPA register actually approved. Reference approval NMPA S20250045. Domestic generics vs imported originator.

4domestic approvals

Forms listed: 1
Product: Dulaglutide Injection
Form: injection
Strength: 1.5 mg (0.5ml) /unit (prefilled pen)
Holder: Shandong Boan Biotechnology
Origin: China
Approved: 2025-08-05
Approval no: NMPA S20250045

2imported approvals

approval count only; per-product detail not captured

Biomarker trends

no biomarker readings yet

Studies

The studies on Dulaglutide, what they found, in whom and how strongly, are on its evidence page, each linked to its source.

What the trials measure

Registered primary outcomes this development's trials are powered on, commonest first (ClinicalTrials.gov). What is measured, across markets.

Registered primary endpoint	Markets measuring it
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse…	IL, IN, JP, KR
Change from Baseline in Hemoglobin A1c (HbA1c)	IN, JP, KR
Number of Participants With One or More Adverse Events (AEs) - Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events…	IN
Number of Participants With One or More Hypoglycemic Events, Including Severe Hypoglycemic Events.	IN
Percentage of Participants Reporting AEs and SAEs From Baseline to Week 24	IN
Number of Participants With One or More Gastrointestinal (GI) AEs From Baseline to Week 24	IN
Change in HbA1c	IN
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses) at Week 26	IN
Fluid intake	CH
Point prevalence abstinence rate at week 12	CH

Connections

Trajectory

2014

MarketUK: approved-other (MHRA-authorised (UK), per eMC SmPC)

EMC:dulaglutide (product 7482) · machine-extracted

2015

MarketCH: approved-other (Swissmedic-authorised (Switzerland))

Swissmedic:dulaglutid (2015-05-06) · machine-extracted

2015

MarketKR: approved-other (MFDS-approved (South Korea))

MFDS:dulaglutide (2015-05-26) · machine-extracted

2015

MarketJP: approved-other (PMDA-approved (Japan))

PMDA:dulaglutide (2015-07-03) · machine-extracted

2016

MarketSG: approved-other (HSA-registered (Singapore))

HSA:dulaglutide (2016-03-18) · machine-extracted

2018

Relatedshares a mechanism with Semaglutide

NCT03495102 · machine-extracted

2018

ProfileDulaglutide (GLP-1 agonist)

NCT03495102 · machine-extracted

2020

MarketIL: approved-other (Israel MoH-registered)

IsraelMoH:dulaglutide (2020-08-31) · machine-extracted

2025

MarketCN: approved-other (NMPA-approved (domestic + imported))

NMPA:NMPA S20250045 · machine-extracted

2026

MarketCH: rct (clinical trials (highest phase 2))

NCT04687514 · machine-extracted

2026

MarketIL: rct (clinical trials (highest phase 3))

NCT02787551 · machine-extracted

2026

MarketJP: rct (clinical trials (highest phase 3))

NCT07668336 · machine-extracted

2026

MarketKR: rct (clinical trials (highest phase 3))

NCT07668336 · machine-extracted

2026

MarketSG: rct (clinical trials (highest phase 3))

NCT07282041 · machine-extracted

2026

MarketUS: approved-other (approved, marketed)

BLA125469 · machine-extracted

2026

MarketIN: rct (clinical trials (highest phase 3))

NCT07668336 · machine-extracted

Get into the weeds: raw observations + provenance

dula_uk  2026-07-14  kind=geography_stage  verify=M
   UK marketing authorisation (MHRA), per the eMC SmPC: TRULICITY 0.75 mg solution for injection in pre-filled pen [active substance: dulaglutide], first authorised 2014-11-21. [electronic Medicines Compendium, medicines.org.uk]
   source EMC:dulaglutide (product 7482)  https://www.medicines.org.uk/emc/product/7482/smpc

swissmedic__dev_dulaglutide__CH  2026-07-13  kind=geography_stage  verify=M
   Swissmedic-authorised in Switzerland: dulaglutidum (Trulicity 1.5 mg, solution for injection, single-use prefilled pen), first authorisation 2015-05-06. [Swissmedic list of authorised medicinal products]
   source Swissmedic:dulaglutid (2015-05-06)  https://www.swissmedic.ch/dam/swissmedic/en/dokumente/internetlisten/erweiterte_ham_ind.xlsx.download.xlsx/erweiterte_ham_ind.xlsx

mfds__dev_dulaglutide__KR  2026-07-13  kind=geography_stage  verify=M
   MFDS-approved in South Korea: Dulaglutide (Trulicity 0.75mg/0.5mL (dulaglutide, recombinant) single-dose pen), first approval 2015-05-26. [MFDS drug product-approval list]
   source MFDS:dulaglutide (2015-05-26)  https://nedrug.mfds.go.kr/pbp/CCBGA01

pmda__dev_dulaglutide__JP  2026-07-13  kind=geography_stage  verify=M
   PMDA-approved in Japan: Dulaglutide (genetical recombination) (Trulicity Subcutaneous Injection 0.75 mg Ateos (Eli Lilly Japan K.K.)), first approval 2015-07-03. [PMDA List of Approved Drugs]
   source PMDA:dulaglutide (2015-07-03)  https://www.pmda.go.jp/files/000281190.pdf

hsa__dev_dulaglutide__SG  2026-07-13  kind=geography_stage  verify=M
   HSA-registered in Singapore: Dulaglutide (TRULICITY INJECTION 1.5MG/0.5ML), first registration 2016-03-18. [HSA Listing of Registered Therapeutic Products]
   source HSA:dulaglutide (2016-03-18)  https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view

dula_edge_sema  2026-06-29  kind=edge  verify=M
   both GLP-1 receptor agonists
   source NCT03495102  https://clinicaltrials.gov/study/NCT03495102

dula_facets  2026-06-29  kind=facets  verify=M
   Dulaglutide facets
   source NCT03495102  https://clinicaltrials.gov/study/NCT03495102

israelmoh__dev_dulaglutide__IL  2026-07-13  kind=geography_stage  verify=M
   Registered in Israel (Israeli Drug Registry): DULAGLUTIDE 1.5 MG/ML (TRULICITY 0.75 MG), current registration 2020-08-31. [Israel MoH Drug Registry]
   source IsraelMoH:dulaglutide (2020-08-31)  https://israeldrugs.health.gov.il/

dula_cn  2026-06-29  kind=geography_stage  verify=M
   NMPA-approved in China (dulaglutide): 4 domestic approval(s) (e.g. Dulaglutide Injection, 1.5 mg (0.5ml) /unit (prefilled pen) , Shandong Boan Biotechnology, China); 2 imported approval(s). Reference NMPA S20250045.
   source NMPA:NMPA S20250045  https://www.nmpa.gov.cn/datasearch/home-index.html

ctsearch__CH__dev_dulaglutide  2026-07-10  kind=geography_stage  verify=M
   dulaglutide: 4 registered trial(s) in CH, highest phase 2 [NCT04687514]
   source NCT04687514  https://clinicaltrials.gov/study/NCT04687514

ctsearch__IL__dev_dulaglutide  2026-07-10  kind=geography_stage  verify=M
   dulaglutide: 4 registered trial(s) in IL, highest phase 3 [NCT02787551]
   source NCT02787551  https://clinicaltrials.gov/study/NCT02787551

ctsearch__JP__dev_dulaglutide  2026-07-10  kind=geography_stage  verify=M
   dulaglutide: 7 registered trial(s) in JP, highest phase 3 [NCT07668336]
   source NCT07668336  https://clinicaltrials.gov/study/NCT07668336

ctsearch__KR__dev_dulaglutide  2026-07-10  kind=geography_stage  verify=M
   dulaglutide: 6 registered trial(s) in KR, highest phase 3 [NCT07668336]
   source NCT07668336  https://clinicaltrials.gov/study/NCT07668336

ctsearch__SG__dev_dulaglutide  2026-07-10  kind=geography_stage  verify=M
   dulaglutide: 3 registered trial(s) in SG, highest phase 3 [NCT07282041]
   source NCT07282041  https://clinicaltrials.gov/study/NCT07282041

openfda__BLA125469__US  2026-07-13  kind=geography_stage  verify=M
   FDA-approved in the US (DULAGLUTIDE); approved, marketed [BLA125469]
   source BLA125469  https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=BLA125469

dula_in  2026-06-29  kind=geography_stage  verify=M
   Dulaglutide: registered phase 3 trials in India [NCT07668336]
   source NCT07668336  https://clinicaltrials.gov/study/NCT07668336